Component

Magnesium chloride

Independent biological entity. Read linked claims for experimental scope and context.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. Magnesium treatment lowered HOMA-IR compared with placebo in hypomagnesemic adults with type 2 diabetes receiving glibenclamide.

    Magnesium → HOMA-IR estimate of insulin resistance source_derived_draftungraded
    Experimental context and source evidence
    cross_nutrient
    Magnesium -> insulin/glucose endpoints; treatment context matters.
    experimental_model
    63-person, 16-week randomized trial.
    exposure
    Eligibility serum Mg at most 0.74 mmol/L. End-study HOMA-IR means 3.8 versus 5.0.
    limitations
    HOMA is a surrogate, not a clamp; renal impairment was excluded. Not proof that all diabetes responds to Mg.
    nutrient_topic
    Magnesium research collection; topical membership is not evidence of a direct dietary effect. · Magnesium
    organism
    Homo sapiens
    plain_language
    One trial found improved insulin-resistance estimates in a specific low-magnesium group.
    primary_references
    [mg-rodriguezmoran2003] Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial (2003). https://pubmed.ncbi.nlm.nih.gov/12663588/ DOI: 10.2337/diacare.26.4.1147
    tissue_or_cell_type
    Human blood-based metabolic endpoints

    Magnesium: cross-nutrient mechanisms and deficiency (2026-09-17) · lines 1551–1562

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · 63-person, 16-week randomized trial. · source_derived_draft · unverified_draft

    ### mg-diabetes-homa-trial2003 Magnesium treatment lowered HOMA-IR compared with placebo in hypomagnesemic adults with type 2 diabetes receiving glibenclamide. Condition category: normal nutrient_topic: Magnesium research collection; topical membership is not evidence of a direct dietary effect. plain_language: One trial found improved insulin-resistance estimates in a specific low-magnesium group. organism: Homo sapiens tissue_or_cell_type: Human blood-based metabolic endpoints experimental_model: 63-person, 16-week randomized trial. limitations: HOMA is a surrogate, not a clamp; renal impairment was excluded. Not proof that all diabetes responds to Mg. cross_nutrient: Magnesium -> insulin/glucose endpoints; treatment context matters. exposure: Eligibility serum Mg at most 0.74 mmol/L. End-study HOMA-IR means 3.8 versus 5.0. [mg-rodriguezmoran2003] Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial (2003). https://pubmed.ncbi.nlm.nih.gov/12663588/ DOI: 10.2337/diacare.26.4.1147
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards